Insulysin cleaves the APP cytoplasmic fragment at multiple sites.
The amyloid peptide (Abeta) deposited in Alzheimer's disease (AD) is generated by beta- and gamma-secretase processing of a larger integral membrane protein precursor (APP). Intramembrane processing of APP by gamma-secretase also yields an intracellular fragment, CTFgamma (a.k.a. AICD), which is highly conserved and is believed to regulate the transcription of several genes including KAI-1 and GSK3beta. The intracellular domain of APP is also processed by caspase to a 31 aa fragment that was shown to induce apoptosis by several groups. Although large quantities of CTFgamma are generated continuously by neurons, little if any is normally detected in cell lysates, which suggests that it is very rapidly turned over in vivo. Previous studies demonstrated that insulysin (IDE), an Abeta-degrading enzyme, is responsible for cytosol-mediated CTFgamma degradation in vitro. Consistent with this finding, knockout mice lacking IDE accumulate CTFgamma to detectable levels in the brain, although its levels remain lower than its precursor, suggesting that it continues to be turned over in the brain. Moreover, when we treated cultured cells with IDE inhibitors, we did not observe an increase in CTFgamma in cell lysates, suggesting that pathways other than IDE are also involved in CTFgamma turnover. To understand CTFgamma turnover further, we have mapped the IDE cleavage sites with the intention of mutating them to examine alternative pathways in future studies. Edman degradation revealed that IDE cleaves CTFgamma at multiple sites to small peptides ranging from 5 to 14 aa. The cleavage sites do not reveal the existence of any sequence specificity for IDE cleavage. Understanding the turnover mechanisms of CTFgamma is critical to the understanding of the signaling function of APP mediated by this fragment. The current study presents the interesting specificity of CTFgamma turnover by IDE, which has been previously identified as the major degrading enzyme for Abeta as well as CTFgamma. In addition, the study provides evidence for the presence of alternative CTFgamma-degrading pathways in the cell.
Venugopal
Chitra
C
Department of Neurosciences, Medical University of South Carolina, Charleston, South Carolina 29425, USA.
Pappolla
Miguel A
MA
Sambamurti
Kumar
K
D000595:Amino Acid Sequence; D016564:Amyloid beta-Protein Precursor / Q000737:chemistry*; D000818:Animals; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D003593:Cytoplasm / Q000737:chemistry*; D005260:Female; D005452:Fluoresceins; D005456:Fluorescent Dyes; D007339:Insulysin / Q000737:chemistry*; D051379:Mice; D008969:Molecular Sequence Data; D011480:Protease Inhibitors / Q000494:pharmacology; D016622:Silver Staining; D013379:Substrate Specificity
D016564:Amyloid beta-Protein Precursor; D005452:Fluoresceins; D005456:Fluorescent Dyes; D011480:Protease Inhibitors; D007339:Insulysin
Cell. 1993 Dec 17;75(6):1039-42
8261505
J Biol Chem. 2001 Sep 21;276(38):35235-8
11483588
Nature. 2001 Dec 6;414(6864):643-8
11740561
J Cell Sci. 2002 Apr 1;115(Pt 7):1411-22
11896189
J Biol Chem. 2004 Jun 4;279(23 ):24601-11
15044485
J Alzheimers Dis. 2000 Nov;2(3-4):289-301
12214090
Nature. 1993 Jan 21;361(6409):260-3
7678698
Ann N Y Acad Sci. 1992 Dec 31;674:118-28
1283818
FEBS Lett. 1992 Dec 21;314(3):315-21
1334849
Mol Cell Biol. 1996 Nov;16(11):6229-41
8887653
J Biol Chem. 1995 Dec 29;270(52):30853-6
8537337
Curr Drug Targets. 2004 Aug;5(6):517-28
15270198
J Biol Chem. 2006 May 26;281(21):14776-86
16595682
J Neurosci. 2003 Jul 2;23(13):5407-15
12843239
J Biol Chem. 2001 Nov 23;276(47):43756-60
11583985
J Alzheimers Dis. 2006;9(3 Suppl):341-7
16914872
J Biol Chem. 2002 Nov 15;277(46):44195-201
12228233
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4162-7
12634421
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14745-50
9843960
FEBS Lett. 1996 Nov 18;397(2-3):197-200
8955346
J Biol Chem. 1998 Oct 23;273(43):27765-7
9774383
Science. 2001 Jul 6;293(5527):115-20
11441186
J Neurochem. 2006 Feb;96(3):732-42
16405513
J Pharmacol Sci. 2005 Apr;97(4):461-71
15821343
Neuron. 2003 Dec 18;40(6):1087-93
14687544
Science. 1990 Jun 1;248(4959):1122-4
2111583
J Neurosci. 2001 Sep 1;21(17):6597-607
11517249
Proc Natl Acad Sci U S A. 2003 May 13;100(10):6221-6
12732730
FEBS Lett. 1998 May 8;427(2):153-6
9607302
Cell. 1999 Apr 30;97(3):395-406
10319819
FASEB J. 2003 Oct;17 (13):1951-3
12923068
Neurobiol Dis. 2004 Nov;17(2):205-18
15474359
J Biol Chem. 2001 Oct 26;276(43):40288-92
11544248
Neuron. 2002 Jan 31;33(3):321-4
11832221
J Neurochem. 2001 Sep;78(5):1168-78
11553691
Nat Med. 2000 Apr;6(4):397-404
10742146
Physiol Rev. 2001 Apr;81(2):741-66
11274343
J Biol Chem. 2001 Jan 5;276(1):481-7
11035007
Cell. 2002 Jul 12;110(1):55-67
12150997
Nature. 2006 Oct 19;443(7113):870-4
17051221
EMBO Rep. 2001 Sep;2(9):835-41
11520861
J Biol Chem. 1999 Aug 13;274(33):23426-36
10438520
Cell. 2006 Oct 20;127(2):305-16
17055432
J Biol Chem. 1999 Mar 19;274(12):7952-7
10075692
Neuromolecular Med. 2002;1(1):1-31
12025813
Curr Psychiatry Rep. 2004 Apr;6(2):125-33
15038915
J Neurochem. 1999 Sep;73(3):985-93
10461887
Exp Neurol. 2004 Feb;185(2):208-19
14736502
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3922-7
10097139
Biochem J. 1999 Oct 15;343 Pt 2:371-5
10510302
J Biol Chem. 2006 Nov 17;281(46):35176-85
16951405
J Cell Biol. 2003 Oct 13;163(1):27-33
14557245
J Biol Chem. 2007 Feb 16;282(7):4318-25
17170108
J Cell Biol. 2005 Oct 24;171(2):327-35
16230462
J Biol Chem. 2002 Apr 19;277(16):13389-93
11809755
Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4697-702
11917117
Biochemistry. 2002 Feb 26;41(8):2825-35
11851430
J Neurochem. 2005 May;93(4):769-92
15857382